)
Edge
Extra Everything: The Story of Chipotle
Chipotle's story from a single restaurant to a nationwide chain, through crisis and turnaround, built on one of the strongest models in the industry.
Imugene
Imugene (IMU) investor relations material
Imugene Q3 2026 TU earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 TU earnings summary29 Apr, 2026
Executive summary
Positive Phase 1b clinical trial results for azer-cel in CAR T-naive cohorts: 100% ORR in CLL/SLL and 80% ORR in MZL, with protocol expansion to include BTKi combination and MCL indication.
Strategic focus on lead asset azer-cel, with discontinuation of CF33 (VAXINIA) program to prioritize high-value opportunities.
Azer-cel data selected for oral presentation at ASCO 2026, highlighting clinical merit and visibility.
Financial highlights
Cash and cash equivalents at 31 March 2026: $5.963 million, following the first tranche of a $16 million capital raise.
Net cash used in operating activities for the quarter: $9.673 million; R&D expenses comprised 76% of total operating costs.
R&D tax refund of A$2,738,618 received for FY2025.
Additional $5.62 million and $4.0 million from SPP received post-quarter end.
Outlook and guidance
Key near-term catalysts include ASCO abstract publication (21 May 2026), oral presentation (29 May–2 June 2026), and updated naive cohort data.
Enrollment in BTKi combination cohort and further data readouts expected.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Imugene
- Net loss rose to $149.7M on higher R&D, with strong cash reserves and key clinical milestones ahead.IMU
H2 202427 Mar 2026 - Net loss improved 54% year-over-year as clinical programs advanced and new funding was secured.IMUH2 202527 Mar 2026
- Net loss improved 22% to $37.8M, with strong clinical progress and ongoing funding needs.IMUH1 20268 Mar 2026
- Clinical progress and cost reductions drive outlook, but funding runway remains tight.IMUQ2 2026 TU8 Mar 2026
- Board changes, clinical advances, and financial strength drive strategic expansion in 2024.IMUAGM 202414 Jan 2026
- Promising clinical data and FDA Fast Track status drive focus on registrational studies and partnerships.IMUNWR Virtual Healthcare Conference26 Dec 2025
- FDA guidance de-risks azer-cel, enabling phase III entry and boosting commercial prospects.IMUFDA Meeting Update9 Dec 2025
- Azer-cel trials achieved 81% response rate; $24.9M raised, cash at $32.4M.IMUQ1 2026 TU7 Dec 2025
- Partnership targets solid tumors with a novel oncolytic virus and CD19 CAR-T therapy in China.IMUCollaboration27 Nov 2025
Imugene
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Explore our global coverage